Oncología Traslacional
ONCTRAS
University of Pennsylvania
Filadelfia, Estados UnidosPublicacións en colaboración con investigadores/as de University of Pennsylvania (13)
2024
2022
-
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis
Cancer Letters, Vol. 529, pp. 70-84
2020
-
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey
-
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385
2019
-
Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)
Nature Immunology
-
Complementing the cancer-immunity cycle
Frontiers in Immunology, Vol. 10, Núm. APR
-
Niraparib in patients with newly diagnosed advanced ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402
-
‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development
Nature Immunology
2014
-
The role of complement in tumor growth
Advances in Experimental Medicine and Biology
2013
-
Complement inhibition in cancer therapy
Seminars in Immunology, Vol. 25, Núm. 1, pp. 54-64
-
Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis
International Journal of Radiation Oncology Biology Physics, Vol. 87, Núm. 4, pp. 690-696
-
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis
International Journal of Radiation Oncology Biology Physics, Vol. 85, Núm. 2, pp. 444-450
2012
-
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression
Journal of Immunology, Vol. 189, Núm. 9, pp. 4674-4683